Cosmetic composition for wrinkle reduction containing gypenoside isolated from Gynostemma pentaphyllum
Inventors
Park, Young Jun • Yu, Kee Won • Kim, Jae Hun • KIM, Yeon Sook • Lee, Seung Ki • Lim, Joo Hyuck • Kim, Jong Mook • Choi, Chi Ho • Kim, Ju Yeon • Kim, Jung Yun • Moon, Sung Ho
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11007136-B2
Publication Date
2021-05-18
Expiration Date
Abstract
The present invention relates to a cosmetic composition for wrinkle reduction comprising, as an active ingredient, a Gynostemma pentaphyllum gypenoside fraction and, more specifically, to a cosmetic composition for wrinkle reduction, wherein the Gynostemma pentaphyllum gypenoside fraction includes at least one gypenoside selected from the group consisting of gypenoside UL1, gypenoside UL2, gypenoside UL3, gypenoside UL4, gypenoside UL5, gypenoside UL6, and gypenoside UL7.
Core Innovation
The invention relates to a cosmetic composition for reducing wrinkles by topically administering an effective amount of a Gynostemma pentaphyllum gypenoside fraction. The gypenoside fraction comprises 20 to 30 wt% of at least one of gypenoside UL4 and gypenoside UL5, where each gypenoside is defined by its chemical identity and structure.
The disclosed composition is used to reduce wrinkles, including general wrinkles and transparent wrinkles. The approach relies on a cosmetic composition containing the defined gypenoside UL4 and/or UL5 within the specified wt% range of the gypenoside fraction.
The description reports promotion of procollagen production and improvements in skin elasticity and dermal density, including reduction of periorbital wrinkles in clinical use. The gypenoside-containing formulations are reported as stable in terms of content and appearance under various storage conditions.
Claims Coverage
The document identifies one independent claim describing a wrinkle-reducing method using a topically administered cosmetic composition. Across the claims, the inventive concept is refined by specifying a quantitative effective amount range for the gypenoside fraction relative to the total composition weight and by narrowing the wrinkle target to a transparent wrinkle. The independent claim is grounded by the requirement that the Gynostemma pentaphyllum gypenoside fraction contains 20–30 wt% gypenoside UL4 and/or UL5 with specific defined chemical structures.
Topically administered wrinkle-reducing cosmetic composition with a defined gypenoside fraction
A method for reducing a wrinkle comprising topically administering to a subject in need thereof a cosmetic composition comprising an effective amount of a Gynostemma pentaphyllum gypenoside fraction comprising 20 to 30 wt% of at least one of gypenoside UL4 and gypenoside UL5, where gypenoside UL4 and gypenoside UL5 are defined by specified chemical identities and structures.
Effective amount concentration range of the gypenoside fraction relative to total composition weight
The method further specifies that the Gynostemma pentaphyllum gypenoside fraction is present at an effective amount ranging from 0.01 to 30 wt% of the total composition weight.
Transparent wrinkle reduction
The method includes forming a wrinkle that is transparent.
Overall, the claim coverage centers on topical wrinkle reduction using a Gynostemma pentaphyllum gypenoside fraction containing 20–30 wt% UL4 and/or UL5 with defined chemical structures, with refinement by an effective-amount concentration range for the gypenoside fraction and by targeting transparent wrinkles.
Stated Advantages
Promotion of procollagen production.
Reduction of wrinkles, including reduction of periorbital wrinkles in clinical use.
Improved skin elasticity.
Improved dermal density.
Transparent wrinkle reduction by increased dermal density.
Lack of cytotoxicity and skin irritation.
Good stability of the gypenoside-containing formulation under various storage conditions.
Documented Applications
Use of the cosmetic composition to reduce wrinkles in a subject, including reduction of periorbital wrinkles in clinical use.
Reduction of transparent wrinkles, with transparent wrinkle reduction associated with increased dermal density.
Interested in licensing this patent?